Study summary
Ianalumab became the first drug to succeed in two Sjögren's phase 3 trials
What was tested
Ianalumab, an antibody that removes B cells and blocks their BAFF survival signal, against placebo in two phase 3 trials (NEPTUNUS-1 and -2) for active Sjögren's disease.
What they found
- Both trials met their main goal of lowering systemic disease activity.
- The FDA granted Breakthrough Therapy designation and filings followed.
What it means
Likely the first approved treatment aimed at the disease itself rather than dryness symptoms.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.